
MDNAF
Healthcare · Biotechnology · $25.1M market cap
$0.2670-0.03 (-9.4%)Nov 13, 12:47 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +15.5% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 25, 2026 | After the close | -0.05 | -0.04 | +20.0% |
| Feb 12, 2026 | After the close | -0.04 | -0.04 | 0.0% |
| Nov 12, 2025 | After the close | -0.05 | -0.04 | +20.0% |
| Jul 31, 2025 | Time not confirmed | -0.04 | -0.06 | -37.6% |
| Jun 25, 2025 | After the close | -0.04 | 0.01 | +125.0% |
| Feb 12, 2025 | After the close | -0.05 | -0.05 | 0.0% |
| Nov 14, 2024 | After the close | -0.04 | -0.04 | 0.0% |
| Jul 31, 2024 | After the close | -0.04 | -0.04 | 0.0% |
| Jun 27, 2024 | Time not confirmed | -0.05 | -0.20 | -300.0% |
| Feb 14, 2024 | Before the open | -0.06 | -0.05 | +16.7% |
| Nov 14, 2023 | Before the open | -0.05 | -0.04 | +20.0% |
| Jul 28, 2023 | Before the open | -0.06 | -0.05 | +16.7% |
| Feb 7, 2023 | Before the open | -0.06 |
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate…
| -0.05 |
| +16.7% |
| Nov 4, 2022 | Before the open | -0.05 | -0.05 | 0.0% |
| Aug 15, 2022 | Before the open | -0.06 | -0.05 | +16.7% |
| May 13, 2022 | Time not confirmed | -0.05 | -0.05 | +7.2% |
| Feb 9, 2022 | Before the open | -0.11 | -0.07 | +36.4% |
| Nov 12, 2021 | Before the open | -0.09 | -0.12 | -33.3% |
| Aug 13, 2021 | Time not confirmed | -0.10 | -0.10 | +4.1% |
| May 28, 2021 | After the close | -0.09 | -0.09 | 0.0% |
| Feb 12, 2021 | Before the open | -0.05 | -0.09 | -80.0% |
| Nov 13, 2020 | After the close | -0.07 | -0.06 | +14.3% |
| Aug 4, 2020 | After the close | -0.02 | -0.04 | -100.0% |
| May 15, 2020 | Before the open | -0.03 | -0.05 | -66.7% |
| Feb 13, 2020 | Before the open | -0.07 | -0.04 | +42.9% |
| Nov 5, 2019 | Before the open | -0.08 | -0.03 | +62.5% |
| Aug 9, 2019 | After the close | -0.08 | -0.05 | +37.5% |
| Jun 24, 2019 | After the close | -0.06 | -0.03 | +50.0% |
| Feb 14, 2019 | After the close | -0.03 | -0.03 | 0.0% |
| Nov 13, 2018 | After the close | -0.03 | -0.03 | 0.0% |
| Aug 13, 2018 | Before the open | — | -0.03 | — |
| Jun 27, 2018 | After the close | -0.08 | -0.04 | +50.0% |
| Feb 12, 2018 | Before the open | -0.11 | -0.07 | +36.4% |